[CPRX] Catalyst Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.09 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart CPRX

Refresh chart

Strongest Trends Summary For CPRX

CPRX is in the medium-term up 47% in 5 months and up 91% in 1 year. In the long-term up 349% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. The company focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. Its principal product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. The company also develops CPP-115, a vigabatrin analog to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, such as post-traumatic stress disorder and Tourette syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-22.5% ROE-25.68% ROI
Current Ratio12.99 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities36.06 M Cash From Investing Activities-40 K Cash From Operating Activities-3.79 M Gross Profit
Net Profit-5.41 M Operating Profit-4.29 M Total Assets76.05 M Total Current Assets75.97 M
Total Current Liabilities5.85 M Total Debt Total Liabilities9.43 M Total Revenue
Technical Data
High 52 week6.11 Low 52 week1.92 Last close5.03 Last change-0.98%
RSI75.81 Average true range0.28 Beta0.62 Volume310.27 K
Simple moving average 20 days7.3% Simple moving average 50 days22.15% Simple moving average 200 days42.18%
Performance Data
Performance Week-0.59% Performance Month23.59% Performance Quart60.19% Performance Half103.64%
Performance Year71.67% Performance Year-to-date161.98% Volatility daily2.68% Volatility weekly6%
Volatility monthly12.3% Volatility yearly42.6% Relative Volume298.06% Average Volume1.66 M
New High New Low


2019-11-11 17:21:47 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX

2019-11-08 10:33:32 | 3 ‘Strong Buy’ Stocks to Buy on Weakness

2019-11-07 18:15:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX

2019-11-01 12:32:09 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX

2019-10-31 10:45:00 | Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Catalyst Pharmaceuticals, Inc. CPRX

2019-10-31 08:03:05 | Catalyst Pharmaceuticals to Hold Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, November 13th, 2019

2019-10-30 06:03:05 | Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® Amifampridine Phosphate in Patients with Congenital Myasthenic Syndromes CMS

2019-10-29 15:16:07 | Investors Can Find Strong Stocks with our First Profit Screen

2019-10-29 09:46:01 | Catalyst Pharma CPRX to Post Q3 Earnings: What's in Store?

2019-10-25 08:38:43 | Did The Underlying Business Drive Catalyst Pharmaceuticals's NASDAQ:CPRX Lovely 416% Share Price Gain?

2019-10-19 21:56:58 | Top Insider Buys Highlight for the Week of Oct. 18

2019-10-01 15:06:07 | Learn How to Find Top-Ranked 'Cheap' Stocks Under $10 with this Screener

2019-09-25 08:02:00 | Catalyst Pharmaceuticals to Participate in the 2019 Cantor Global Healthcare Conference

2019-09-23 14:55:00 | Catalyst Pharmaceuticals, Inc. Comments on Trading in its Common Stock and on its Capital Resources

2019-09-19 10:37:31 | Should You Wait Before Investing In Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX?

2019-09-18 09:31:01 | Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

2019-09-13 10:00:02 | Catalyst Pharmaceutical CPRX is a Great Momentum Stock: Should You Buy?

2019-09-13 08:41:12 | Implied Volatility Surging for Catalyst CPRX Stock Options

2019-09-13 07:40:02 | The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans

2019-09-13 06:03:00 | Catalyst Pharmaceuticals, Inc. Determines Not to Proceed with Previously Announced Public Offering of Common Stock

2019-09-11 16:19:39 | Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

2019-09-10 15:18:07 | Investors Can Find Big Returns with this First Profit Screen

2019-09-06 21:48:55 | Edited Transcript of CPRX earnings conference call or presentation 8-Aug-19 12:30pm GMT

2019-09-06 09:31:01 | Why Is Catalyst CPRX Up 23% Since Last Earnings Report?

2019-08-29 08:44:12 | Catalyst Pharmaceuticals CPRX Looks Good: Stock Adds 6% in Session

2019-08-28 08:03:00 | Catalyst Pharmaceuticals to Participate in the 14th Annual Citi Biotech Conference on September 4th, 2019

2019-08-27 14:39:06 | Here's How to Find Top-Ranked Stocks Under $10 to Buy

2019-08-19 12:00:04 | Top Ranked Momentum Stocks to Buy for August 19th

2019-08-16 07:54:11 | Will Catalyst Pharmaceuticals Continue to Surge Higher?

2019-08-13 11:42:40 | Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX: The Best Of Both Worlds

2019-08-08 15:06:00 | Why Catalyst Pharmaceuticals Stock Broke Down Today

2019-08-08 09:26:01 | Catalyst's CPRX Q2 Earnings and Revenues Beat Estimates

2019-08-07 18:55:10 | Catalyst Pharmaceutical CPRX Beats Q2 Earnings and Revenue Estimates

2019-08-07 16:18:24 | Catalyst Pharmaceuticals Announces Second Quarter 2019 Financial Results and Provides Corporate Update

2019-08-01 16:09:00 | 2 Small-Cap Stocks That Could Make You Rich

2019-08-01 08:03:00 | Catalyst Pharmaceuticals Announces Its Support of Spinal Muscular Atrophy Awareness Month

2019-07-31 09:12:00 | 2 Top Stocks to Buy in August

2019-07-31 08:03:00 | Catalyst Pharmaceuticals to Hold Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 8th, 2019

2019-07-08 08:58:33 | Do Directors Own Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX Shares?

2019-07-08 08:40:12 | Do Options Traders Know Something About Catalyst CPRX Stock We Don't?

2019-07-05 12:04:04 | Catalyst Pharma Focuses on Firdapse Launch & Label Expansion

2019-07-02 12:14:04 | Explosive Stocks Under $10

2019-06-26 14:07:59 | Here is What Hedge Funds Think About Catalyst Pharmaceuticals, Inc. CPRX

2019-06-13 17:46:09 | Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi

2019-06-12 09:46:42 | UPDATE 2-Catalyst Pharma sues FDA over approval of cheaper rival drug

2019-06-12 09:30:01 | Catalyst CPRX Up 14.1% Since Last Earnings Report: Can It Continue?

2019-06-12 09:00:53 | Catalyst Pharma files lawsuit against U.S. FDA on Jacobus Pharma drug approval

2019-06-12 08:47:00 | Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food and Drug Administration

2019-06-04 08:03:00 | Catalyst Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference

2019-05-30 08:03:00 | Catalyst Pharmaceuticals Announces Expansion of Firdapse License to Include Japan